Can we add domperidone to the repeat prescription for a 26-year-old female who has been taking domperidone 10 mg three times daily (as needed) for dyspepsia for three years?

Do Not Add Domperidone to Repeat Prescription

This patient should not continue domperidone on repeat prescription after 3 years of use, as this directly violates regulatory safety guidance limiting treatment duration to a maximum of 7 days. 1

Critical Safety Concerns

Regulatory Duration Limits

The MHRA (Medicines and Healthcare products Regulatory Agency) issued strict guidance in 2014 that domperidone:

• Should only be used for prevention of nausea and vomiting
• Must be limited to 7 days maximum duration
• Maximum daily dose restricted to 30 mg
• This patient has been taking it for 3 years - far exceeding safe duration 1

Cardiac and Hormonal Risks with Prolonged Use

Long-term domperidone carries significant risks:

• QTc prolongation and cardiac arrhythmias (reported in long-term studies) 2
• Hyperprolactinemia - particularly concerning in young women, causing menstrual irregularities, galactorrhea, and potential fertility issues 3
• The 2023 study specifically found elevated prolactin levels after just 28 days of 30 mg daily domperidone 3

Appropriate Management Algorithm

Step 1: Stop Domperidone Immediately

• Explain regulatory contraindication for long-term use
• Document the medication review

Step 2: Follow Evidence-Based FD Treatment Pathway

According to 2022 British Society of Gastroenterology guidelines 4:

First-line options:

• Proton pump inhibitors (PPIs) - strong recommendation, high-quality evidence - use lowest effective dose 4
• H2-receptor antagonists - weak recommendation, low-quality evidence 4
• H. pylori eradication if positive - strong recommendation, high-quality evidence 4

Second-line if first-line fails:

• Tricyclic antidepressants (amitriptyline 10 mg once daily, titrate to 30-50 mg) - strong recommendation, moderate-quality evidence as gut-brain neuromodulators 4

Step 3: Non-Pharmacological Measures

• Regular aerobic exercise - strong recommendation 4
• Early dietitian involvement to avoid overly restrictive diets 4

Common Pitfall to Avoid

The most dangerous pitfall here is continuing domperidone simply because the patient has been on it for years. In the 2016 UK quality improvement study, 37% of active repeat prescriptions had MHRA contraindications, and 100% of repeat prescriptions exceeded recommended duration 1. This represents poor prescribing practice that must be corrected.

Clinical Context

While the 2026 long-term gastroparesis study 2 showed 36% of patients continued domperidone for mean 7.6 years with benefit, this was:

• Under FDA IND (Investigational New Drug) protocol with intensive monitoring
• For gastroparesis, not functional dyspepsia
• With regular EKG monitoring and safety assessments
• Not applicable to routine primary care prescribing

The answer is definitively no - stop the domperidone and transition to guideline-concordant therapy with PPIs as first-line treatment. 4